The BIOKÉ webshop is under construction until January 2nd, 2018. We wish you a successful 2018!
Every year BIOKÉ speaks at professional seminars and comes to world wide exhibitions in the life science industry.
Are you eager to meet us? On the left sidebar our events calendar is shown, hope to see you next time!
DANVERS, MA (PRWEB) – April 5, 2018, Cell Signaling Technology (CST), a leading provider of antibodies, kits, and services, has opened a new office in Shanghai China to support the rapidly expanding China life science market and the growth of the CST business in the country.
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous adverse reactions (SCARs) involving keratinocyte apoptosis and detachment of the epidermis. Current treatments, which include the use of corticosteroids, are controversial in their effectiveness. Numerous studies have demonstrated that the mechanism of SJS-TEN involves effector cytotoxic T lymphocytes (CTLs). In addition, treatment with anti–TNF-α biologic agents appears to be beneficial in patients with TEN and TEN-like acute cutaneous lupus erythematosus. However a randomized, systemic trial had not yet been run.
FEBRUARY 15, 2018, DANVERS, MA – Cell Signaling Technology, Inc. (CST), a leading provider of antibodies, kits, and services, is honored with the 2018 CiteAb Award for “Antibody Company of the Year” and “Antibody Company Succeeding in Cancer Biology.” CST was also highly commended for the “Chemical Probes Supplier to Watch” and “Antibody Company with Sustained Success in China.” The CiteAb Antibody Awards aim to celebrate the very best suppliers, reagents, and individuals in the research antibody sector, recognizing the efforts that are made to progress science.
DECEMBER 8, 2017 - By expressing a secreted form of an EpCAM-specific BiTE molecule in the cancer cells it infects, a novel oncolytic virus both kills cells directly and induces a robust cytotoxic T cell response.
DECEMBER 14, 2017 - Using xCELLigence Real-Time Cell Analysis (RTCA), Sanofi Pasteur scientists have developed an assay for accurate viral titer determination that is 5-times less labor intensive and 3.5-times cheaper than conventional methods
SAN DIEGO December 12, 2017 - Using xCELLigence Real-Time Cell Analysis (RTCA) scientists at Genentech have developed an automated and high throughput assay for studying the molecular determinants of bronchoconstriction/dilation. Read more.
SAN DIEGO NOVEMBER 30, 2017 - ACEA Biosciences (ACEA), a pioneer and leader in label-free real-time cell analysis instrumentation, and Ncardia, a leading expert in human cardiovascular stem cell technology, disease modelling and cell-based assay products and services, announced today that they have established a global partnership to provide comprehensive solutions for cardiac drug discovery and cardiac safety assessment. This multifaceted partnership will include the joint development of applications, co-marketing, and commercial activities.
Ipswich, MA, USA (November 7, 2017) — New England Biolabs (NEB®) today announced the release of the NEBNext Ultra II FS DNA Library Prep Kit for next generation sequencing (NGS). This new kit employs a novel enzymatic fragmentation system that combines fragmentation, end repair and dA-tailing in a single tube, and utilizes a single protocol regardless of input amount or GC content.
Xiamen, China – November 2, 2017 - Cell Signaling Technology (CST), a leading provider of antibodies, kits, and services, has announced that Jay Dong, General Manager of its China operations, has been elected Co-President of the Chinese Society for Cell Biology’s Academia-Industry Consortium for Innovation and Entrepreneurship. This consortium was formed to support translation of basic research into translational medicine. Dong was inaugurated by Dr. Yeguang Chen, President of Chinese Society for Cell Biology (CSCB) at CSCB 2018 Conference in Xiamen, China.
SAN DIEGO, OCTOBER 20, 2017 - Employing the xCELLigence® technology from ACEA Biosciences, a team of Spanish scientists have developed a real-time assay for screening anti-biofilm treatments and quantifying their efficacy. Biofilms are surface-attached communities of bacterial or fungal cells that are enmeshed in an extensive extracellular matrix which makes them more resistant to both antibiotics and the immune system. With biofilms estimated to be responsible for >60% of microbial infections, and 80% of chronic infections in humans, finding ways to disrupt established biofilms is of critical importance. In recent years there has been a growing interest in exploiting bacteriophages, or the lytic proteins that they encode, to treat biofilms.
Leiden, The Netherlands, August 21, 2017 - Pluriomics and ACEA Biosciences (ACEA) today announced a cooperation to advance together cardiac drug discovery and expand Pluriomics service portfolio. This cooperation will give Pluriomics access to ACEA xCELLigence® Real-Time Cell Analysis (RTCA) CardioECR instrument which enables them to simultaneously assess cardiomyocyte contractility, viability, and electrophysiology.
CHELMSFORD, Mass., October 5th, 2017 – Brooks Automation, Inc. announced today that it has acquired 4titude, Ltd., a privately-held manufacturer of scientific consumables for biological sample materials used in a variety of genomic and DNA analytical applications. Based in Surrey, England and over 12 years of operations and approximately 85 employees, 4titude is widely recognized for its innovative range of Polymerase Chain Reaction (PCR) plates, seals and related bench-top instrumentation. 4titude has delivered consistent growth over the last 5 years with sales and distribution globally to 1200 customers in 50 different countries.
Danvers, MA – September 5, 2017 – Cell Signaling Technology (CST), a leading provider of antibodies, kits, and services, has announced changes in part of its European operations. On January 1st, 2018, CST will now deal directly with its customers in Germany and Austria.
August 18, 2017 State College PA - SoftGenetics announced that it has purchased the assets of Mitotyping Technologies, originally founded by Terry Melton, from Health Network laboratories of Allentown PA. The addition of Mitotyping Technologies furthers SoftGenetics goal of becoming a dominant source to the world-wide DNA forensic community, which in addition to Mitotyping Technologies includes software tools for STR Analysis, Mitochondrial and STR analysis of nextgeneration data and the soon to be released MaSTR™ continuous mixture probabilistic software.
IPSWICH, MA, USA (August 1, 2017) — Detecting a specific DNA sequence outside of the laboratory, without bulky equipment or even electricity, may seem unlikely. However, astronauts aboard the International Space Station (ISS) did just that using a technique developed by New England Biolabs (NEB).
IPSWICH, Mass. and HEIDELBERG, Germany, July 25, 2017 /PRNewswire/ -- The EMBL Advanced Training Centre (ATC) welcomes New England Biolabs (NEB®) as its newest member of their Corporate Partnership Programme. Founded in the mid-1970s as a collective of scientists committed to developing innovative products for the life sciences industry, NEB is a recognized world leader in the discovery, development and commercialization of recombinant and native enzymes for genomic research.
Ipswich, MA, USA and Norwich, UK (June 7th, 2017) – In its mission to tackle global challenges through life science research, the Earlham Institute (Norwich, UK) faces unique problems raised through the sheer breadth of biological samples that it works with. Samples that the institute processes can come from any number of species of plant, animal, or microbial organism.
SAN DIEGO JUNE 14, 2017 - ACEA Biosciences today announced the completion of its Phase 1 clinical study of AC0058, a novel irreversible Bruton’s Tyrosine Kinase (BTK) inhibitor, which is in development for the treatment of B cell-related autoimmune diseases, including rheumatoid arthritis and systemic lupus erythematosus. Fifty-six (56) healthy subjects participated in the double-blind, placebo-controlled trial, which......
IPSWICH, Mass., May 30, 2017 - The kits are compatible with poly(A) mRNA isolation and ribosomal RNA (rRNA) depletion, and libraries can be constructed from a substantially broader input range (5 ng to 1 µg of total RNA) at high yields. New Ultra II technology addresses lower input amounts and challenging sample types for Illumina® next generation sequencing systems.
ROSWELL, Ga. June 13, 2017 – As a life sciences company, Cell Signaling Technology (CST) uses about 200,000 pairs of gloves each year. But that glove waste no longer goes into a landfill. CST diverts it through an innovative program that has enabled the company to recycle more than 4,400 pounds of gloves, which are then turned into flower pots, lawn furniture, and other products.
SAN DIEGO, May 3, 2017 - The NovoCyte system with its updated software and firmware provides broader versatility and flexibility with its multi-option optical configuration capabilities. This update also brings the release of the new ACEA NovoCyte 3005 3 lasers system that provides up to 17 parameters including forward and side scatter.
LEIDEN, April 3, 2017 - BIOKÉ, a business unit of Cell Signaling Technology Europe (CST Europe), and Bethyl Laboratories, Inc. announced that they have signed an agreement allowing BIOKÉ to exclusively distribute Bethyl’s products in the BeNeLux countries, effective immediately.
LEIDEN, March 22, 2017 - BIOKÉ, a business unit of Cell Signaling Technology Europe (CST Europe), and ACEA Biosciences, Inc., a high performance cell analysis platforms manufacturer, announced their partnership to exclusively distribute ACEA’s xCELLigence® Cell Analyzer in the BeNeLux countries, effective immediately.
February 10, 2017, Danvers, MA — Cell Signaling Technology (CST), a leading provider of antibodies, kits, and services, was honored with the 2017 CiteAb Award for “PTM Antibody Company of the Year” and for a third year in a row with the award for “Researchers’ Choice.” CST was also a close runner-up for the “Antibody Company of the Year” award. The CiteAb Antibody Awards aim to celebrate the very best suppliers, reagents, and individuals in the research antibody sector, recognizing the efforts that are made to progress science.
January 26, 2017, State College PA - SoftGenetics announced the availability of its new GeneMarkerHTS software for analysis of the Mitochondrial Genome for Forensic and Clinical Research applications from High Throughput Sequencing systems. GeneMarkerHTS is believed to be the first commercially available software developed exclusively for analysis of NGS Mitochondrial sequencing, is applicable in many cases including mass disaster, missing person, as well as clinical disease research and forensic anthropology applications.
January 19, 2017, State College PA - SoftGenetics announced the availability of the latest version of ChimerMarker software. ChimerMarker software, automated chimerism analysis software, integrates speed and accuracy with a biologist‐friendly interface. The software can be used to monitor chimerism levels in both allogeneic and autologous stem cells transplant or hematopoietic stem ...
DANVERS, Mass - November 21, 2016 – Honored as a life science leader at the 2016 Life Science Industry Awards (LSIA), Cell Signaling Technology (CST), a worldwide provider of antibodies, received Best Customer Service for its outstanding commitment to antibody quality and customer satisfaction. The LSIA recognizes .......
LEIDEN, October 24, 2016 - BIOKÉ, a Cell Signaling Technology Europe (CST Europe) company, and ACEA Biosciences, Inc., a high performance cell analysis platforms manufacturer, announced their partnership to exclusively distribute ACEA’s NovoCyte™ Flow Cytometer in the BeNeLux countries, effective immediately.
June 13, 2016 - Cell Signaling Technology (CST), CST, a worldwide provider of antibodies, is providing four high school juniors from Boston North Shore communities—Gloucester, Lynn, Peabody and Salem—with $10,000 each to pursue a college education in a science-related program.
April 12, 2016 - Cell Signaling Technology, Inc. (CST), a worldwide provider of antibodies, released four new monoclonal antibodies relevant to the rapidly growing fields of immunometabolism and tumor immunology.
NOVEMBER 3, 2015, NATIONAL HARBOR, MD (US BUSINESS WIRE) Cell Signaling Technology, Inc. (CST), a worldwide provider of antibodies, announced today the release of 6 new monoclonal antibodies (mAb) for tumor immunology research. This announcement was made at the 30th annual meeting of the Society for Immunotherapy of Cancer (SITC) at National Harbor, MD November 4-8th, 2015.